moderna

moderna

NASDAQ:MRNA
Moderna

Chart

Detailed Quote

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Featured Articles and Interviews
Glowing DNA strand against blue background with digital graphs and glowing bars.

Hantavirus Outbreak Sparks Rollercoaster Ride for Biotech Stocks

Dollar bills, pink and white pills in blister packs, and a nasal spray on a blue background.

Blackstone Raises Record US$6.3 Billion for Largest Life Sciences Fund

Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Press Releases

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

Moderna Appoints Michael McDonnell to Board of Directors

Moderna Science Day Highlights Expanding Potential of mRNA Platform

The Conversation (0)